NZ628124A - Pharmaceutical compositions to reduce complications of ocular steroid - Google Patents
Pharmaceutical compositions to reduce complications of ocular steroidInfo
- Publication number
- NZ628124A NZ628124A NZ628124A NZ62812413A NZ628124A NZ 628124 A NZ628124 A NZ 628124A NZ 628124 A NZ628124 A NZ 628124A NZ 62812413 A NZ62812413 A NZ 62812413A NZ 628124 A NZ628124 A NZ 628124A
- Authority
- NZ
- New Zealand
- Prior art keywords
- steroid
- ocular
- pharmaceutical compositions
- reduce complications
- ocular steroid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003431 steroids Chemical class 0.000 title abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 abstract 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597189P | 2012-02-10 | 2012-02-10 | |
| PCT/US2013/025390 WO2013119988A1 (en) | 2012-02-10 | 2013-02-08 | Pharmaceutical compositions to reduce complications of ocular steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628124A true NZ628124A (en) | 2016-06-24 |
Family
ID=48948063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628124A NZ628124A (en) | 2012-02-10 | 2013-02-08 | Pharmaceutical compositions to reduce complications of ocular steroid |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10058616B2 (enExample) |
| EP (1) | EP2797601B1 (enExample) |
| JP (1) | JP6231995B2 (enExample) |
| KR (1) | KR102060210B1 (enExample) |
| CN (2) | CN104125830B (enExample) |
| AU (1) | AU2013216861B2 (enExample) |
| BR (1) | BR112014018393B1 (enExample) |
| CA (1) | CA2862055C (enExample) |
| CY (1) | CY1120323T1 (enExample) |
| DK (1) | DK2797601T3 (enExample) |
| ES (1) | ES2673330T3 (enExample) |
| IN (1) | IN2014MN01571A (enExample) |
| NZ (1) | NZ628124A (enExample) |
| PT (1) | PT2797601T (enExample) |
| RU (1) | RU2660585C2 (enExample) |
| TR (1) | TR201808592T4 (enExample) |
| TW (1) | TWI620578B (enExample) |
| WO (1) | WO2013119988A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201809136UA (en) * | 2016-04-19 | 2018-11-29 | Univ Nanyang Tech | Subconjuctival depot forming formulations for ocular drug delivery |
| US11766421B2 (en) | 2017-09-25 | 2023-09-26 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| CA3080166A1 (en) | 2017-11-21 | 2019-05-31 | Axerovision, Inc. | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| EP3820479B1 (en) | 2018-07-09 | 2026-03-11 | Taiwan Liposome Co., Ltd. | Methods to reduce complications of intra-articular steroid |
| IL281513B1 (en) | 2018-09-16 | 2026-07-01 | Tlc Biopharmaceuticals Inc | Preparations for the treatment of joint pain |
| JP2022516099A (ja) | 2018-12-27 | 2022-02-24 | サーフィス オフサルミクス，インコーポレイテッド | 眼科用医薬組成物及び癌表面疾患の処置方法 |
| RU2716429C1 (ru) * | 2019-05-29 | 2020-03-11 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения рецидивирующей эрозии роговицы различного генеза |
| CN111415822A (zh) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用 |
| US20240156839A1 (en) * | 2021-03-05 | 2024-05-16 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions with reduced side effect and methods of using the same |
| CN117979951A (zh) | 2021-05-10 | 2024-05-03 | 瑟菲斯眼科股份有限公司 | 一种用于缓解眼部疼痛的硫酸软骨素的用途 |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
| IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
| AU2003298738A1 (en) * | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
| EP1590006B1 (en) | 2003-02-04 | 2010-09-08 | Bracco Suisse SA | Ultrasound contrast agents and process for the preparation thereof |
| KR100862930B1 (ko) * | 2004-06-23 | 2008-10-13 | 시리온 테라퓨틱스, 인크. | 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물 |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| EP1864668B1 (en) * | 2006-06-01 | 2012-11-21 | Novagali Pharma S.A. | Use of prodrugs for ocular intravitreous administration |
| AU2007260872A1 (en) * | 2006-06-22 | 2007-12-27 | Sirion Therapeutics, Inc | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| US20080118500A1 (en) * | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| WO2009107753A1 (ja) * | 2008-02-29 | 2009-09-03 | 財団法人 名古屋産業科学研究所 | 後眼部到達用リポソーム及び後眼部疾患用医薬組成物 |
| CN101502485A (zh) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | 地塞米松眼用纳米立方液晶制剂及其制备方法 |
| CN101926769A (zh) * | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 地塞米松磷酸钠脂质体注射液 |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| SG184127A1 (en) * | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2013
- 2013-02-08 AU AU2013216861A patent/AU2013216861B2/en active Active
- 2013-02-08 CN CN201380008147.9A patent/CN104125830B/zh active Active
- 2013-02-08 CN CN201710573136.5A patent/CN107260679B/zh active Active
- 2013-02-08 IN IN1571MUN2014 patent/IN2014MN01571A/en unknown
- 2013-02-08 PT PT137470217T patent/PT2797601T/pt unknown
- 2013-02-08 DK DK13747021.7T patent/DK2797601T3/en active
- 2013-02-08 KR KR1020147022121A patent/KR102060210B1/ko active Active
- 2013-02-08 JP JP2014556741A patent/JP6231995B2/ja active Active
- 2013-02-08 ES ES13747021.7T patent/ES2673330T3/es active Active
- 2013-02-08 TR TR2018/08592T patent/TR201808592T4/tr unknown
- 2013-02-08 BR BR112014018393-7A patent/BR112014018393B1/pt active IP Right Grant
- 2013-02-08 WO PCT/US2013/025390 patent/WO2013119988A1/en not_active Ceased
- 2013-02-08 EP EP13747021.7A patent/EP2797601B1/en active Active
- 2013-02-08 US US14/377,211 patent/US10058616B2/en active Active
- 2013-02-08 TW TW102105245A patent/TWI620578B/zh active
- 2013-02-08 NZ NZ628124A patent/NZ628124A/en unknown
- 2013-02-08 CA CA2862055A patent/CA2862055C/en active Active
- 2013-02-08 RU RU2014132553A patent/RU2660585C2/ru active
-
2018
- 2018-03-06 US US15/913,466 patent/US10350294B2/en active Active
- 2018-06-11 CY CY20181100606T patent/CY1120323T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01571A (enExample) | ||
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| WO2012021107A8 (en) | A liposomal formulation for ocular drug delivery | |
| PH12014500510A1 (en) | Use of omega fatty acids for treating disease | |
| AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
| WO2013061205A8 (en) | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| DOP2012000225A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
| WO2008070463A3 (en) | Endoxifen methods and compositions | |
| WO2012091523A8 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
| IN2014DN00277A (enExample) | ||
| BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
| CA2854430C (en) | Liposomal corticosteroids for treatment of inflammatory disorders in humans | |
| BR112013003934A2 (pt) | depot de fosfolipídeos | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| MX389866B (es) | El uso de 9-cis-retinil acetato para mejorar la funcion visual de un sujeto que padece de perdida de la funcion visual originada por una deficiencia retinoide endogena de 11-cis retinal. | |
| FI3634396T3 (fi) | Koostumus L-DOPA-hoidon tehon parantamiseen | |
| AU2012277905A8 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| MX376783B (es) | Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2018 BY CPA GLOBAL Effective date: 20170106 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2019 BY CPA GLOBAL Effective date: 20180104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2020 BY CPA GLOBAL Effective date: 20190103 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2021 BY CPA GLOBAL Effective date: 20200102 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2022 BY CPA GLOBAL Effective date: 20210108 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2023 BY CPA GLOBAL Effective date: 20220107 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2024 BY CPA GLOBAL Effective date: 20230112 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2025 BY CPA GLOBAL Effective date: 20240104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250102 |